Lv1
50 积分 2024-11-24 加入
Rethinking ovarian cancer III: the past decade and future directions
23小时前
待确认
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse
4天前
已完结
Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1
14天前
已完结
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
[Clinical application guideline for breast cancer biomarker testing Chinese Society of Pathology, The Society of Breast Cancer China Anti-Cancer Association, Pathology Quality Control Center]
3个月前
已完结
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients
3个月前
已完结
Hereditary breast and ovarian cancer: from genes to molecular targeted therapies
3个月前
已完结
BRCA1/2 Mutations and Breast/Ovarian Cancer Risk: A New Insights Review
3个月前
已完结
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
3个月前
已完结
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort
3个月前
已完结
皖公网安备34019202002308
